AzTrials
AzTrials

Provoked VestibulodyniaPVD/tDCSNCT02543593

Efficacy of Transcranial Direct-Current Stimulation (tDCS) for Provoked Vestibulodynia : a Triple Blind Randomized Controlled Trial

A study of Provoked Vestibulodynia, run by Université de Sherbrooke at 2 sites in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Provoked vestibulodynia (PVD) is the most common form of vulvodynia and despite its high prevalence and important sexual, conjugal and psychological deleterious repercussions, effective evidence-based interventions remain limited. Read more about this study

Who is it for?
Ages 17 to 45 years, women only
Conditions the study is for
Provoked Vestibulodynia
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
40 participants
Where
2 sitesCanada
Study dates
Nov 2014to Nov 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 17 to 45 years
  • Women only
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Experience moderate to severe pain in at least 90% of attempted sexual intercourse;
  • Experience moderate to severe pain during cotton swab test, in one or more regions of the vestibule (minimum of 5/10 on a subjective numeric scale of pain intensity);
  • Pain limited to the vestibule during vaginal intercourse and during activities exerting pressure on the vestibule (tampon insertion, tight jeans or pants, cycling, horseback riding);
  • Presence of PVD for at least 6 months and diagnosed according to the standardized gynecological examination protocol by one of our staff gynecologists;
  • Have a stable sexual partner with regular sexual activity including penetration.

Who cannot join

  • Other pelvic pathology associated with pelvic pain (e.g., deep dyspareunia);
  • Chronic pain conditions (e.g. fibromyalgia, low back pain, chronic migraines);
  • Use of medication that can influence the perception of pain (eg analgesic, opioids, antiepileptic, muscle relaxant);
  • Pregnancy for less than one year and breastfeeding;
  • Anterior vulvar or vaginal surgery;
  • Refusal to refrain from other treatments one month prior to first treatment study until the last 3-month follow-up assessment;
Show all 9Show fewer
  • Important urogynecologic symptoms (urinary or anal incontinence, urinary urgency, pelvic organ prolapse, active urinary tract or vaginal infection or earlier in the last 3 months, etc.);
  • Contraindications to tDCS (e.g. metallic implant in or near the skull, history of epilepsy, pacemaker);
  • Previously received tDCS treatment.

Trial locations and contacts

2 sites in 1 country.

Canada2 sites
  • Centre hospitalier Universitaire de Sherbroke

    Sherbrooke, Quebec, J1H 5n4

  • Centre Hospitalier Universitaire de Sherbrooke

    Sherbrooke, Quebec, J1H 5N4

Other trials in Canada

About this study

Provoked vestibulodynia (PVD) is the most common form of vulvodynia and despite its high prevalence and important sexual, conjugal and psychological deleterious repercussions, effective evidence-based interventions remain limited. For a high proportion of women, significant pain persists despite the currently available treatments. Transcranial direct-current stimulation (tDCS) was shown to be effective in various chronic pain conditions. So far, only one case report study has shown significant pain reduction in women with vulvodynia. The main goal of this randomized controlled trial is to evaluate the efficacy of tDCS in women with PVD compared to sham tDCS. Forty women diagnosed with PVD, by a gynecologist following a standardized protocol will be randomized to either active or sham tDCS for ten 20 minute sessions of 2 mA stimulation over a 2-week period. Outcome measures will be collected at baseline, after treatment and at 3-month follow-up. The primary outcome is pain during intercourse assessed with a numerical rating scale (NRS). Secondary measurements focus on sexual function, vestibular pain sensitivity, psychological distress, treatment satisfaction and Patient Global Impression of Change (PGIC). The investigators expect that active tDCS treatment will significantly reduce pain during intercourse (post-treatment and 3-month follow-up compared to pre-treatment assessment). This trial will provide important information for determining the efficacy of a novel and promising intervention for women with PVD.

Being tested
Active tDCS or Sham tDCS
Keywords
tDCS

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Active tDCS or Sham tDCSDevice

    Also called neuroConn; Model no: 0008; Serial no:0169

    tDCS is a painless technique which consists in applying low direct-current through electrodes (one electrode serving as an anode, the other as a cathode) placed on the scalp to target the cerebral cortex. In patients with chronic pain, the anode is commonly placed over the motor cortex (M1) (Valeriani et al., 1999).

Study groups in NCT02543593
Study groupRoleWhat they receive
InterventionExperimentalParticipants will receive active transcranial direct-current stimulation (tDCS) for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
Receives: Device: Active tDCS or Sham tDCS
PlaceboSham comparatorParticipants will receive sham transcranial direct-current stimulation (tDCS) for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
Receives: Device: Active tDCS or Sham tDCS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain during intercourse (Numeric rating scale)

    Pain during intercourse will be assessed using a numeric rating scale (NRS) ranging from 0 to 10, where 0 is no pain at all, and 10 is the worst pain ever. This method for measuring pain has been shown to detect significant treatment effects in women with PVD and demonstrates a significant positive correlation with other pain intensity measures. Pain during intercourse is the main symptom of PVD and the one that most interferes with quality of life, hence the most relevant measure of functional outcome (Bergeron et al., 2008; Bergeron et al., 2001; Morin et al., 2010; Morin et al., 2011).

    Measured: Change in the NRS scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment

Secondary outcomes (9)
  1. Pain (McGill-Melzack questionnaire)

    The McGill-Melzack questionnaire allows the assessment of sensory, affective and evaluative components of pain. This world-renowned questionnaire, studied for its validity, reliability and responsiveness to change, is commonly used in RCTs (Bergeron et al., 2001; Melzack, 1975; Davidoff et al., 1987; Hays et al., 1994; Bansal et al., 2009; Moy et al., 2011; Foster et al., 2010).

    Measured: Change in the McGill-Melzack scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment

  2. Vestibular sensitivity (algometer)

    A gradual pressure (1 to 1000 g) will be applied to three distinct points of the vestibule at the 3, 6 and 9 o'clock positions (Cyr et al., 2014). Each of these pressure points will be applied randomly (e.g. 3,6,9 or 3,9,6 or 6,9,3.). During this procedure, each participant will be asked to indicate when they start to feel pain (pain threshold) and subsequently the maximal pressure that can be tolerated (pain tolerance). Pain intensity is assessed throughout the test using a Computerized Visual analog scale (CoVas). This assessment has shown good reliability and validity (Cyr et al., 2014).

    Measured: Change in the pain threshold and pain tolerance scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment

  3. Female Sexual Function Index (FSFI)

    The Female Sexual Function Index (FSFI) is a multidimensional measure of sexual function evaluating desire, arousal, lubrication, orgasm, satisfaction and pain. In addition to good psychometric properties (reliability, internal consistency and responsiveness to change (Rosen et al., 2000; Goldfinger et al, 2009), normative data are available for this questionnaire suggesting clinical level of dysfunctions (Wiegel et al., 2005).

    Measured: Change in the FSFI scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment

  4. Pain Catastrophizing Scale (PCS)

    Pain catastrophizing will be assessed using the Pain Catastrophizing Scale (Sullivan, Bishop, \& Pivik, 1995), which consists of 13 items measuring exaggerated negative thoughts and feelings about the meaning of pain. Items are scored on a 5-point scale with the end points (0) not at all and (4) all the time. The PCS is a reliable and valid measure that has demonstrated a stable factorial structure across clinical and general populations, including a French population (French et al., 2005; Osman et al., 2000; Sullivan, et al., 1995).

    Measured: Change in the PCS scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment

  5. Spielberg State-Trait Anxiety Inventory (IASTA)

    Anxiety will be assessed using the Spielberger State-Trait Anxiety Inventory (STAI - (Spielberger, Gorsuch, \& Lushene, 1970); ASTA - (Gauthier \& Bouchard, 1993)). The STAI is a 40-item, well-known and widely used measure of state and trait anxiety that has demonstrated very good psychometric properties (Cronbach's alpha State = .93, Trait = .97) in various clinical and non-clinical samples including pain populations (Gauthier \& Bouchard, 1993; Greenberg \& Burns, 2003; Rule \& Traver, 1983; Tanaka-Masumi \& Kameoka, 1986).

    Measured: Change in the IASTA state and IASTA trait scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment

  6. Beck Depression Inventory questionnaire (BDI-II)

    Depression or depression symptoms will be measured with the Beck Depression Inventory-II (BDI-II). The BDI-II is comprised of 21 items, with scores for most items ranging from 0 (low intensity) to 3 (high intensity) (Beck, Steer \& Brown, 1996; Beck, Steer \& Garvin, 1988). This measure of depression has been validated for use in chronic pain populations (Turner \& Romano, 1984).

    Measured: Change in the BDI scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment

  7. Pain Anxiety Symptoms Scale (PASS-20)

    The Pain Anxiety Symptoms Scale (PASS-20), evaluating fear of pain, also shows good psychometric properties (Coons, Hadjistavropoulos \& Asmundson, 2004; McCracken \& Dhingra, 2002).

    Measured: Change in the PASS-20 scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment

  8. Patient's global impression of change (PGIC)

    Patient self-reported improvement [scale of 0 (completely dissatisfied) to 10 (completely satisfied)] and treatment satisfaction [scale of 0 (worse) to 10 (complete cure)] will be measured at the 2-week post-treatment and 3-month post-treatment structured interview in order to assess the clinical significance of results.

    Measured: Change in the PGIC scores from 2-week post-treatment to 3-month post-treatment

  9. Global Measure of Sexual Satisfaction scale (GMSS)

    Sexual satisfaction will be assessed using the Global Measure of Sexual Satisfaction scale, which consists of 5 items assessing global sexual satisfaction. Internal consistency of this scale is high (alpha = 0.90), as is test-retest reliability (r = 0.84) (Lawrance \& Byers, 1998).

    Measured: Change in the GMSS scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Sep 2015 (estimated)
  2. Study startNov 2014
  3. Primary completionJun 2016
  4. Study completionNov 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02543593
Sponsor's protocol ID
14-169
Acronym
PVD/tDCS
Status last verified
May 2017
First submitted
4 Sep 2015
Last updated
2 May 2017
Results posted
No
Data monitoring committee
No

Publications

  • Morin A, Leonard G, Gougeon V, Waddell G, Bureau YA, Girard I, Morin M. Efficacy of transcranial direct-current stimulation (tDCS) in women with provoked vestibulodynia: study protocol for a randomized controlled trial. Trials. 2016 May 14;17(1):243. doi: 10.1186/s13063-016-1366-5.

    PubMed 27179944

Questions about this trial

What is this clinical trial studying?

A study of Provoked Vestibulodynia, run by Université de Sherbrooke at 2 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 May 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain during intercourse (Numeric rating scale) (time frame: Change in the NRS scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02543593, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 May 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in